Centennial Bank AR Sells 44 Shares of Danaher Co. (NYSE:DHR)

Centennial Bank AR cut its holdings in shares of Danaher Co. (NYSE:DHR) by 22.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 150 shares of the conglomerate’s stock after selling 44 shares during the period. Centennial Bank AR’s holdings in Danaher were worth $37,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the company. Oak Thistle LLC bought a new stake in Danaher during the 2nd quarter worth approximately $363,000. Caden Capital Partners LP lifted its position in shares of Danaher by 12.4% in the fourth quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after purchasing an additional 15,313 shares in the last quarter. HighPoint Advisor Group LLC bought a new stake in shares of Danaher in the fourth quarter worth $2,614,000. Norden Group LLC bought a new stake in shares of Danaher in the first quarter worth $4,151,000. Finally, Duality Advisers LP bought a new stake in shares of Danaher in the first quarter worth $5,573,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

NYSE:DHR opened at $274.54 on Wednesday. The company has a market capitalization of $203.35 billion, a PE ratio of 46.53, a P/E/G ratio of 4.55 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The company has a 50 day simple moving average of $270.98 and a two-hundred day simple moving average of $258.24.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $2.05 EPS. Research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 in the last quarter. 11.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on DHR shares. Robert W. Baird upped their price target on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Stifel Nicolaus upped their price objective on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Wells Fargo & Company assumed coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective for the company. Finally, Leerink Partners increased their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.